Insider Selling: Progyny, Inc. (NASDAQ:PGNY) COO Sells $36,952.00 in Stock


Share on StockTwits

Progyny, Inc. (NASDAQ:PGNY) COO Peter Anevski sold 800 shares of Progyny stock in a transaction on Thursday, April 1st. The shares were sold at an average price of $46.19, for a total value of $36,952.00. Following the completion of the sale, the chief operating officer now directly owns 667,079 shares of the company’s stock, valued at $30,812,379.01. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Peter Anevski also recently made the following trade(s):

  • On Monday, April 5th, Peter Anevski sold 26,833 shares of Progyny stock. The shares were sold at an average price of $46.08, for a total value of $1,236,464.64.
  • On Wednesday, March 10th, Peter Anevski sold 8,999 shares of Progyny stock. The shares were sold at an average price of $47.43, for a total value of $426,822.57.
  • On Wednesday, February 3rd, Peter Anevski sold 21,000 shares of Progyny stock. The shares were sold at an average price of $47.84, for a total value of $1,004,640.00.
  • On Monday, February 1st, Peter Anevski sold 21,000 shares of Progyny stock. The stock was sold at an average price of $47.93, for a total value of $1,006,530.00.
  • On Wednesday, January 6th, Peter Anevski sold 21,000 shares of Progyny stock. The stock was sold at an average price of $43.30, for a total value of $909,300.00.

NASDAQ:PGNY opened at $44.87 on Thursday. The stock has a 50-day simple moving average of $46.21 and a 200-day simple moving average of $39.10. The stock has a market cap of $3.91 billion, a P/E ratio of 407.91 and a beta of 1.83. Progyny, Inc. has a 1 year low of $17.90 and a 1 year high of $53.48.

Progyny (NASDAQ:PGNY) last released its quarterly earnings data on Wednesday, February 24th. The company reported $0.07 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.06 by $0.01. The business had revenue of $100.30 million during the quarter. Progyny had a return on equity of 7.43% and a net margin of 1.03%. As a group, research analysts forecast that Progyny, Inc. will post 0.14 EPS for the current fiscal year.

Several large investors have recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company boosted its position in shares of Progyny by 1.5% during the 4th quarter. The Manufacturers Life Insurance Company now owns 17,114 shares of the company’s stock worth $725,000 after acquiring an additional 249 shares in the last quarter. Redmond Asset Management LLC boosted its position in shares of Progyny by 1.2% during the 4th quarter. Redmond Asset Management LLC now owns 24,344 shares of the company’s stock worth $1,032,000 after acquiring an additional 285 shares in the last quarter. Parallel Advisors LLC boosted its position in shares of Progyny by 89.5% during the 4th quarter. Parallel Advisors LLC now owns 978 shares of the company’s stock worth $41,000 after acquiring an additional 462 shares in the last quarter. Victory Capital Management Inc. lifted its holdings in shares of Progyny by 8.3% in the 4th quarter. Victory Capital Management Inc. now owns 7,402 shares of the company’s stock valued at $314,000 after purchasing an additional 568 shares during the last quarter. Finally, California State Teachers Retirement System lifted its holdings in shares of Progyny by 1.7% in the 3rd quarter. California State Teachers Retirement System now owns 40,413 shares of the company’s stock valued at $1,189,000 after purchasing an additional 683 shares during the last quarter. 58.54% of the stock is owned by institutional investors and hedge funds.

Several research firms recently commented on PGNY. Bank of America raised Progyny from a “neutral” rating to a “buy” rating in a research note on Tuesday, March 16th. Zacks Investment Research cut Progyny from a “hold” rating to a “sell” rating in a research note on Saturday, February 27th. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $37.71.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.

Featured Story: Price Target

Insider Buying and Selling by Quarter for Progyny (NASDAQ:PGNY)

Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.